Quest Diagnostics IncorporatedSEC Filings
|
|
All SEC filings by Quest Diagnostics Incorporated (DGX) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Jul 23, 2026 | |
| 10-Q | Quarterly report | View Diff | Apr 22, 2026 | |
| 10-K | Annual report | View Diff | Feb 26, 2026 | |
| 10-Q | Quarterly report | View Diff | Oct 21, 2025 | |
| 10-Q | Quarterly report | View Diff | Jul 23, 2025 | |
| 10-Q | Quarterly report | View Diff | Apr 23, 2025 | |
| 10-K | Annual report | View Diff | Feb 20, 2025 | |
| 10-Q | Quarterly report | View Diff | Oct 23, 2024 | |
| 10-Q | Quarterly report | View Diff | Jul 24, 2024 | |
| 10-Q | Quarterly report | View Diff | Apr 24, 2024 |
Events
| 8-K | Quest Diagnostics Reports Second Quarter 2026 Financial Results | Jul 23, 2026 | ||
| 8-K | Submission of Matters to a Vote of Security Holders | May 21, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | May 8, 2026 | ||
| 8-K | Quest Diagnostics Prices $500 Million of Senior Notes | May 1, 2026 | ||
| 8-K | Results of Operations and Financial Condition | Apr 21, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Mar 12, 2026 | ||
| 8-K | Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share | Feb 10, 2026 | ||
| 8-K | Results of Operations and Financial Condition | Jan 12, 2026 | ||
| 8-K | Results of Operations and Financial Condition | Oct 21, 2025 | ||
| 8-K | Results of Operations and Financial Condition | Jul 22, 2025 |
Registrations and Prospectuses
| 424B2 | Prospectus for primary offering | Apr 28, 2026 | ||
| FWP | Free writing prospectus | Apr 27, 2026 | ||
| FWP | Free writing prospectus | Apr 27, 2026 | ||
| 424B2 | Prospectus for primary offering | Apr 27, 2026 | ||
| S-3ASR | Automatic shelf registration | Jun 20, 2025 | ||
| 424B2 | Prospectus for primary offering | Aug 16, 2024 | ||
| FWP | Free writing prospectus | Aug 15, 2024 | ||
| 424B2 | Prospectus for primary offering | Aug 15, 2024 | ||
| 424B2 | Prospectus for primary offering | Oct 31, 2023 | ||
| FWP | Free writing prospectus | Oct 30, 2023 |
Proxies
| DEFA14A | Additional proxy soliciting materials | Apr 6, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 6, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Apr 11, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 4, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 4, 2025 | |
| PX14A6G | Letter to shareholders | Apr 11, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 5, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 5, 2024 | |
| PRE 14A | Preliminary proxy | View Diff | Mar 25, 2024 | |
| PX14A6G | Letter to shareholders | Apr 10, 2023 |
Other
| CT ORDER | Confidential treatment order | Mar 27, 2017 | ||
| NO ACT | No action letter | Mar 23, 2017 | ||
| UPLOAD | Letter from SEC | Apr 29, 2016 | ||
| CORRESP | Correspondence with SEC | Apr 20, 2016 | ||
| UPLOAD | Letter from SEC | Apr 7, 2016 | ||
| NO ACT | No action letter | Mar 17, 2016 | ||
| CT ORDER | Confidential treatment order | Dec 7, 2015 | ||
| SD | Conflict minerals disclosure | May 29, 2014 | ||
| NO ACT | No action letter | Feb 19, 2014 | ||
| UPLOAD | Letter from SEC | May 7, 2013 |
Ownership
| 4 | Davis J. E. | Sep 3, 2026 | ||
| 144 | Notice of proposed sale of securities | Sep 1, 2026 | ||
| 4 | Prevoznik Michael E | Aug 31, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 28, 2026 | ||
| SC 13G/A | Beneficial ownership report | Aug 14, 2026 | ||
| 4 | Delaney Mark E | Jul 29, 2026 | ||
| 144 | Notice of proposed sale of securities | Jul 28, 2026 | ||
| 4 | Kuppusamy Karthik | Jul 27, 2026 | ||
| 4 | Carter Robert B | Jul 27, 2026 | ||
| 4 | Gregg Vicky B | Jul 27, 2026 |